🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

448 results for “RAD” Clear

  1. A Study of JNJ-90301900 in Combination with Concurrent Chemoradiation Therapy in LA HNSCC

    Janssen-Cilag International N.V.

    Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

    phase 1 other active

    1 trial

  2. A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

    Alphapharm Pty Ltd

    Arm A: Diagnosed with uterine serous carcinoma (USC) Arm B: Diagnosed with recurrent or progressive, high-grade epithelial ovarian cancer (EOC) with cyclin E1-driven selection Arm C: Diagnosed with solid tumor with biomarker-driven selection

    phase 1 other active

    1 trial

  3. A clinical study of MK-6050 in healthy people (MK-6050-001)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  4. A clinical trial of MK-6050 in healthy participants (MK-6050-002)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  5. A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  6. A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

    Novartis Pharmaceuticals

    Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)

    phase 1 other active

    1 trial

  7. A pilot, open label, single dose, randomized, four-period, four-sequence, four-treatment crossover, comparative bioavailability study of UDCA PMCS 500 mg formulation 1 film-coated tablets (test 1 formulation), and UDCA PMCS 500 mg formulation 2 film-coated tablets (test 2 formulation), and UDCA PMCS 500 mg formulation 3 film-coated tablets (test 3 formulation), and reference formulation in healthy, male and female volunteers under fasting conditions.

    s.r.o.

    UDCA causes a reduction in cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and reducing cholesterol secretion into the bile. Presumably, cholesterol gallstones are gradually dissolved by dispersion of the cholesterol and formation of liquid crystals.

    phase 1 other active

    1 trial

  8. A study in healthy men to learn about how the body absorbs, processes, and removes radioactively labeled BAY 3283142

    Bayer AG

    Chronic kidney disease

    phase 1 other active

    1 trial

  9. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  10. A study to assess how radium-223 moves through the patients with prostate cancer receiving radium-223 dichloride treatment.

    Bayer AG

    Prostate cancer

    phase 1 other active

    1 trial

  11. A study to investigate a potential effect of rilzabrutinib (SAR444671) on ethinylestradiol and levonorgestrel from combined oral contraceptives in healthy female participants

    Sanofi-aventis Healthcare Pty Ltd

    Immune Thrombocytopenia Purpura

    phase 1 other active

    1 trial

  12. A trial to learn about how multiple doses of itraconazole change how AZD5004 moves throughout the body over time in healthy adults and how multiple doses of AZD5004 change how ethinyl estradiol and levonorgestrel move throughout the body overtime in healthy female adults

    AstraZeneca AB

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  13. Aflibercept every 2 months

    Regeneron UK Limited

    Radiation Retinopathy

    phase 1 small molecule completed

    1 trial

  14. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

  15. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametinib tablets 2 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with MEKINIST® (Trametinib) tablets 2 mg, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, USA in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma (in combination with dabrafenib);, BRAF V600E mutation-positive unresectable or metastatic solid tumors;, BRAF V600E mutation-positive metastatic non-small cell lung cancer (NSCLC), in combination with dabrafenib;, BRAF V600E mutation-positive low-grade glioma (LGG)., BRAF V600E mutation-positive locally advanced or metastatic anaplastic thyroid cancer (ATC);, BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib;

    phase 1 other active

    1 trial

  16. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  17. BIO 300 Oral Powder

    United Therapeutics Europe Ltd

    Acute Radiation Syndrome

    phase 1 small molecule completed

    1 trial

  18. Bimzelx 320 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in pre-filled syringe, Bimzelx 320 mg solution for injection in pre-filled syringe, Bimzelx 160 mg solution for injection in pre-filled pen, Bimzelx 160 mg solution for injection in

    Lacuna Pharma Pty Ltd

    Hidradenitis suppurativa, Axial spondyloarthritis, Moderate to Severe Plaque Psoriasis, Psoriatic arthritis

    phase 1 small molecule active

    1 trial

  19. CLR 131

    Cellectar Biosciences

    High-Grade Glioma

    phase 1 small molecule active

    1 trial

  20. Ciforadenant

    Corvus Pharmaceuticals

    Renal Cell Cancer

    phase 1 small molecule completed

    1 trial

  21. Ciforadenant

    Corvus Pharmaceuticals

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  22. Combining drug-eluting bead chemoembolization and radioembolization for treatment of colorectal liver metastases: DEBIR90Y study

    Disc Medicine

    colorectal liver metastases

    phase 1 other active

    1 trial

  23. Desogestrel/ethinyl estradiol and ethinyl estradiol

    Teva Pharma GmbH

    Follicle Development

    phase 1 small molecule completed

    1 trial

  24. Donepezil Dihydroxynaphthalate for Injection

    Shanghai University of Traditional Chinese Medicine

    Alzheimer Disease

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources